Midesteine

Drug Profile

Midesteine

Alternative Names: MR 889

Latest Information Update: 25 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medea Research
  • Developer Medea Research; Pulitzer
  • Class Expectorants
  • Mechanism of Action Chymotrypsin inhibitors; Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Bronchitis; Cystic fibrosis; Emphysema

Most Recent Events

  • 06 Nov 1997 Pulitzer is a licensee for midesteine in Italy
  • 27 May 1997 A study in patients with chronic obstructive pulmonary disease has been added to the Respiratory disorders therapeutic trials section
  • 24 Aug 1994 Investigation in Bronchitis in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top